Research
Hormonal
Semaglutide slows the progression of chronic kidney disease (CKD) and reduces major kidney disease events in patients with type 2 diabetes.
If you have type 2 diabetes and chronic kidney disease, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to significantly slow the progression of kidney disease and reduce the risk of major kidney events.
StrongSupportsHIGH confidence
Similarly, the FLOW trial showed a 24% reduction in major kidney disease events (HR 0.76; 95% CI: 0.66–0.88; p = 0.002) with weekly 1.0 mg semaglutide in individuals with T2D with CKD.
Why this rating
Based on the FLOW trial, a large RCT with statistically significant results.
Source
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
Richard J. MacIsaac · Future Cardiology · 2025
DOI 10.1080/14796678.2025.2511412
narrative_reviewCited 11×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (GLP-1 receptor agonist) significantly reduces major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes and established cardiovascular disease.Strong
- Semaglutide promotes significant weight loss in individuals with obesity, both with and without type 2 diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →